ADVANCED OR METASTATIC NSCLS WITH EXON 20 INSERTION MUTATION

Clinical trials for ADVANCED OR METASTATIC NSCLS WITH EXON 20 INSERTION MUTATION explained in plain language.

Never miss a new study

Get alerted when new ADVANCED OR METASTATIC NSCLS WITH EXON 20 INSERTION MUTATION trials appear

Sign up with your email to follow new studies for ADVANCED OR METASTATIC NSCLS WITH EXON 20 INSERTION MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New hope for Tough-to-Treat lung cancer: major trial tests drug combo

Disease control Ongoing

This study is testing if adding a new drug called zipalertinib to standard chemotherapy works better than chemotherapy alone for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). The goal is to see if the combination can …

Matched conditions: ADVANCED OR METASTATIC NSCLS WITH EXON 20 INSERTION MUTATION

Phase: PHASE3 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control

Last updated Mar 30, 2026 14:32 UTC

ADVANCED OR METASTATIC NSCLS WITH EXON 20 INSERTION MUTATION

Get alerted when new ADVANCED OR METASTATIC NSCLS WITH EXON 20 INSERTION MUTATION trials appear

New hope for Tough-to-Treat lung cancer: major trial tests drug combo